A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. 2000

J Gedge, and S Orme, and K K Hampton, and K S Channer, and T J Hendra
Department of Geriatric Medicine, Royal Hallamshire Hospital, Sheffield, UK.

OBJECTIVE To compare a new low-dose warfarin induction regimen with the Fennerty regimen in elderly inpatients. METHODS Age-stratified, randomized prospective study. METHODS 120 age-stratified elderly inpatients. METHODS Each patient was randomized to either the new induction regimen or to a modified Fennerty regimen. METHODS Days to therapeutic International Normalized Ratio (INR >2); days in the therapeutic range (INR 2-3) during induction; number of patients with INR >4.5; ability of day 4 INR to predict day 8 warfarin dose. RESULTS The mean time to therapeutic INR was longer for the new induction regimen than modified Fennerty regimen in patients aged 65-75 years [4.6 (mean) +/- 1.6 (SD) days vs 3.8 +/- 0.8 days; P = 0.03] and in patients aged >75 years (4.5 +/- 1.4 days vs 3.5 +/- 0.7 days; P = 0.003). Patients spent more time in the therapeutic INR range with the new induction regimen [3.0 +/- 1.3 days vs 2.7 +/- 1.3 days (P = 0.03) for those aged 65-75 years and 2.9 +/- 1.1 days vs 2.4 +/- 1.3 days (P = 0.04 for those aged >75 years]. Fewer patients using the new regimen had INRs >4.5 in the first 8 days [1 (3%) vs 6 (20%) for 65-75 years (P < 0.05) and 1 (3%) vs 11 (37%) for >75 years (P < 0.01)]. The ability to predict the maintenance dose to within 1 mg was 55% for both regimens. CONCLUSIONS The low-dose regimen has important clinical advantages over the Fennerty regimen for anticoagulating elderly inpatients.

UI MeSH Term Description Entries
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D013923 Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream. Thromboembolisms

Related Publications

J Gedge, and S Orme, and K K Hampton, and K S Channer, and T J Hendra
February 2005, The American journal of medicine,
J Gedge, and S Orme, and K K Hampton, and K S Channer, and T J Hendra
April 1984, British medical journal (Clinical research ed.),
J Gedge, and S Orme, and K K Hampton, and K S Channer, and T J Hendra
March 2014, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
J Gedge, and S Orme, and K K Hampton, and K S Channer, and T J Hendra
August 2000, Pharmacotherapy,
J Gedge, and S Orme, and K K Hampton, and K S Channer, and T J Hendra
May 1991, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
J Gedge, and S Orme, and K K Hampton, and K S Channer, and T J Hendra
January 1990, Journal of gastroenterology and hepatology,
J Gedge, and S Orme, and K K Hampton, and K S Channer, and T J Hendra
February 2016, Birth defects research. Part A, Clinical and molecular teratology,
J Gedge, and S Orme, and K K Hampton, and K S Channer, and T J Hendra
May 2015, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology,
J Gedge, and S Orme, and K K Hampton, and K S Channer, and T J Hendra
June 2004, Japanese journal of clinical oncology,
Copied contents to your clipboard!